New study presents impressive results of Nexstim SmartFocus® nTMS Language Mapping
Helsinki, Finland: 13 January 2021 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) announces that a new study published in Cancers in January presents impressive results of nTMS language mapping in a large amount of patients. Using the robustness of Nexstim SmartFocus® nTMS data, the authors also introduce a new and more precise classification of what it means to be a ”language eloquent” tumour, challenging the traditional methods that seek to only identify hemispheric dominance for language.
The study “Non-Invasive Mapping for Effective Preoperative Guidance to Approach Highly Language-Eloquent Gliomas—A Large Scale Comparative Cohort Study Using a New Classification for Language Eloquence”, using Nexstim’s NBS System with SmartFocus® nTMS, was published by a neurosurgical team at Technical University of Munich (TUM) in Germany.
The study included 140 consecutive patients with suspected language-eloquent brain tumours. Nexstim SmartFocus® nTMS pre-operative language mapping was performed on all these patients. In a very high number of patients tumour could be removed to the maximum extent, with gross total resection (GTR) achieved in 82.3% of cases.
Further information on Nexstim’s website.